Targeted amino acid substitution overcomes scale-up challenges with the human C5a-derived decapeptide immunostimulant EP67
AM Alshammari, DD Smith, J Parriott… - ACS infectious …, 2020 - ACS Publications
EP67 is a second-generation, human C5a-derived decapeptide agonist of C5a receptor 1
(C5aR1/CD88) that selectively activates mononuclear phagocytes over neutrophils to …
(C5aR1/CD88) that selectively activates mononuclear phagocytes over neutrophils to …
Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant
EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor
(CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 …
(CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 …
Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide
TR Sheen, CK Cavaco, CM Ebrahimi, ML Thoman… - Vaccine, 2011 - Elsevier
The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-
MRSA) is a serious health concern worldwide that requires new therapeutic approaches that …
MRSA) is a serious health concern worldwide that requires new therapeutic approaches that …
[HTML][HTML] Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a
SD Sanderson, ML Thoman, K Kis, EL Virts… - PloS one, 2012 - journals.plos.org
The anaphylatoxin C5a is an especially potent mediator of both local and systemic
inflammation. However, C5a also plays an essential role in mucosal host defense against …
inflammation. However, C5a also plays an essential role in mucosal host defense against …
[HTML][HTML] Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor …
J Gauvin, DN Huynh, I Dubuc, C Lê… - Frontiers in …, 2024 - frontiersin.org
The scientific and medical community faced an unprecedented global health hazard that led
to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory …
to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory …
567 MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7 …
W Dower, A Bakker, S Cwirla, P Joshi, P Pongtornpipat… - 2020 - jitc.bmj.com
Background IL-7 receptor activation is essential for the proper development and
homeostasis of T-cell subpopulations, and maintenance of the TCR clonal repertoire …
homeostasis of T-cell subpopulations, and maintenance of the TCR clonal repertoire …
Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays In Vitro and In Vivo
The complement activation peptide C5a is a key mediator of inflammation that is associated
with numerous immune disorders. C5a binds and activates two seven-transmembrane …
with numerous immune disorders. C5a binds and activates two seven-transmembrane …
2141. Preclinical evaluation of PA-001: a novel, potential macrocyclic peptide-based treatment for COVID-19 which binds to the S2 subunit of SARS-CoV-2 spike …
T Kawamura, M Ohuchi, T Nagasawa… - Open Forum …, 2023 - academic.oup.com
Background Despite the approval of a few COVID-19 drugs, various mutations of SARS-CoV-
2 continue to emerge and pose as a threat to the efficacy of COVID-19 treatments. To …
2 continue to emerge and pose as a threat to the efficacy of COVID-19 treatments. To …
Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in …
EL Morgan, BN Morgan, EA Stein, EL Vitrs, ML Thoman… - Vaccine, 2009 - Elsevier
A conformationally biased, agonist of human C5a65–74 (EP67) was assessed for its
adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) …
adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) …
[HTML][HTML] A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy
WJ Dower, AI Park, AV Bakker, SE Cwirla… - Plos one, 2023 - journals.plos.org
Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been
clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia …
clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia …